- Full List
December 10 2013 at 2:30 PM
The Office of the Vice President for Research is pleased to host the next Nano@Wayne seminar on Tuesday, December 10, 2013 from 2:30 to 3:30 p.m. in the Welcome Center Auditorium.The seminar is free and open to the entire campus community; a reception will immediately follow.
The guest speaker will be Dr. Larry H. Matherly, professor of oncology in WSU's School of Medicine and the Karmanos Cancer Institute. He will present, "A new paradigm for cancer therapy: exploiting the proton-coupled folate transporter for targeted drug delivery to solid tumors."
Membrane transport is essential for antitumor activity of many chemotherapy drugs used for cancer. The Matherly laboratory has long focused on studies of transport processes for folates and folate analogs. These transporters include the ubiquitously expressed reduced folate carrier (RFC), the proton-coupled folate transporter (PCFT), and the high affinity folate receptors (FRs). RFC levels and function are primary determinants of cellular uptake of folate cofactors which are essential for nucleotide biosynthesis. RFC is also a critical determinant of uptake of classic antifolate drugs used for cancer therapy such as methotrexate and newer drugs typified by pemetrexed and pralatrexate. Based on patterns of tumor-selective expression and/or function of FRs and PCFT, recent emphasis has been on identifying novel cytotoxic drugs with selective cellular uptake by these other transporters over RFC. For instance, solid tumors such as ovarian carcinomas generally express high levels of FRs, and many solid tumors including lung, ovarian, and breast cancers abundantly express PCFT. Further, tumors are characterized by acidic microenvironments which would favor membrane transport by PCFT over RFC. Based on these concepts, novel 6- substituted pyrrolo- and thieno[2,3-d]pyrimidine compounds have been synthesized and identified with excellent PCFT- and/or FR transport activity and little to no transport activity by RFC. Experiments have established extraordinarily potent antitumor activities for many of these agents. Dr. Matherly’s talk will cover the rationale for this novel approach to tumor targeting with particular focus on PCFT as a means of for selective delivery of cytotoxic chemotherapy drugs.
- Pharmaceutical Sciences Seminar: Stress and the Neurotoxicity of "Speed"
December 11 2013 at 4:00 PM
Presented by Brian K. Yamamoto, Ph.D., Professor and Chair, Department of Neurosciences, University of Toledo
- Biosafety Training
December 12 2013 at 12:00 PM
This training is required annually for all employees who work with materials that are handled at Biosafety Level 2 (BSL2), including work with human blood, body fluids, tissue, cell lines, animals infected with human pathogens, mammalian viruses, etc. Employees who have taken this class at least once at WSU may take the annual refresher on-line. Topics covered include:
Explanation of Biosafety Principles and Levels from CDC/NIH
Contents of the WSU Biosafety Manual & Exposure Control Plan
Explanation of bloodborne infectious diseases
Procedures to follow in an exposure incident
Safe work practices
Personal protective equipment
Use of biological safety cabinets and other safety equipment
Biohazard waste disposal rules, and much more.
Click here to view the Biosafety Powerpoint Presentation (note: viewing these slides does not count as training!)
Click here for an explanation of Biosafety Levels.
- More Events